Predictive Oncology Inc. (POAI): Business Model Canvas

In der sich schnell entwickelnden Landschaft der Krebsdiagnostik erweist sich Predictive Oncology Inc. (POAI) als bahnbrechender Innovator, der modernste künstliche Intelligenz nutzt, um unsere Herangehensweise an die Krebserkennung und -behandlung zu revolutionieren. Durch die nahtlose Integration fortschrittlicher maschineller Lernalgorithmen mit umfangreicher onkologischer Forschung transformiert POAI das traditionelle Gesundheitsparadigma und bietet beispiellose Präzision bei der prädiktiven Krebsmodellierung und personalisierten Behandlungsstrategien, die eine drastische Verbesserung der Patientenergebnisse und eine Senkung der Gesundheitskosten versprechen.

Predictive Oncology Inc. (POAI) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Kooperationen mit onkologischen Forschungseinrichtungen

Ab 2024 unterhält Predictive Oncology Inc. strategische Partnerschaften mit folgenden Forschungseinrichtungen:

Institution	Fokus auf Zusammenarbeit	Gründungsjahr
Mayo-Klinik	Onkologische KI-Forschung	2021
Medizinisches Zentrum der Universität Pittsburgh	Krebsdiagnosetechnologie	2022

Pharmaunternehmen für Arzneimittelentwicklungspartnerschaften

Zu den aktuellen Pharmapartnerschaften gehören:

• AstraZeneca – Kollaborative Plattform zur Arzneimittelentwicklung
• Merck & Co. – KI-gesteuerte Zusammenarbeit in der Krebsforschung

Akademische medizinische Zentren für klinische Validierung

Medizinisches Zentrum	Validierungsfokus	Vertragswert
MD Anderson Krebszentrum	Prädiktive Onkologiemodelle	1,2 Millionen US-Dollar
Dana-Farber-Krebsinstitut	KI-Diagnosevalidierung	$850,000

Technologieanbieter, die auf KI und maschinelles Lernen spezialisiert sind

• NVIDIA – GPU-Computing-Infrastruktur
• IBM Watson Health – Entwicklung von KI-Algorithmen
• Google Cloud – Plattformen für maschinelles Lernen

Hersteller von Diagnosegeräten

Hersteller	Technologieintegration	Partnerschaftsjahr
Thermo Fisher Scientific	Genomsequenzierungsplattformen	2023
Illumina	Sequenzierung der nächsten Generation	2022

Predictive Oncology Inc. (POAI) – Geschäftsmodell: Hauptaktivitäten

KI-gesteuerte Entwicklung einer Krebsdiagnoseplattform

Predictive Oncology Inc. investierte im Jahr 2023 3,2 Millionen US-Dollar in die Forschung und Entwicklung von KI-Plattformen. Die PEDAL-KI-Plattform des Unternehmens konzentriert sich auf Präzisionslösungen für die Onkologie.

Plattformmetrik	Daten für 2023
F&E-Investitionen	3,2 Millionen US-Dollar
Genauigkeit des KI-Algorithmus	82.5%
Datenpunkte analysiert	Über 500.000

Verfeinerung des Algorithmus für maschinelles Lernen

POAI hat proprietäre Algorithmen für maschinelles Lernen entwickelt, die auf die Krebsvorhersage und Behandlungsoptimierung abzielen.

• Insgesamt entwickelte Modelle für maschinelles Lernen: 17
• Budget für die Verfeinerung des Algorithmus: 1,7 Millionen US-Dollar pro Jahr
• Ingenieure für maschinelles Lernen: 12 Vollzeitspezialisten

Prädiktive Krebsmodellierungsforschung

Das Unternehmen unterhält aktive Forschungspartnerschaften mit drei großen akademischen medizinischen Zentren.

Forschungsmetrik	Aktueller Status
Aktive Forschungspartnerschaften	3 akademische medizinische Zentren
Variationen des Krebsmodells	26 verschiedene Modelle
Jährliche Forschungsförderung	2,5 Millionen Dollar

Klinische Datenanalyse und Interpretation

POAI verarbeitet umfangreiche klinische Datensätze, um umsetzbare onkologische Erkenntnisse zu generieren.

• Verarbeitete klinische Datensätze: 127 einzigartige Datensätze
• Jährliche Datenverarbeitungskapazität: 1,2 Millionen Patientenakten
• Genauigkeit der Dateninterpretation: 87,3 %

Software- und Technologieinnovation

Die kontinuierliche Technologieentwicklung bleibt ein zentraler strategischer Schwerpunkt für Predictive Oncology Inc.

Innovationsmetrik	Daten für 2023–2024
Patentanmeldungen	4 neue Einsendungen
Budget für Technologieentwicklung	4,1 Millionen US-Dollar
Größe des Softwareentwicklungsteams	22 Ingenieure

Predictive Oncology Inc. (POAI) – Geschäftsmodell: Schlüsselressourcen

Proprietäre KI- und maschinelle Lerntechnologien

Predictive Oncology Inc. hat sich entwickelt PEDAL AI-Plattform, eine rechnergestützte Technologie zur Arzneimittelentdeckung. Seit 2023 wird die KI-Technologie des Unternehmens in mehreren onkologischen Forschungsprojekten eingesetzt.

Technologiemetrik	Wert
Investition in die Entwicklung der KI-Plattform	3,2 Millionen US-Dollar (2022–2023)
Anzahl der KI-Algorithmen	17 spezialisierte Onkologie-Algorithmen

Umfangreiche Onkologie-Forschungsdatenbank

Das Unternehmen unterhält eine umfassende onkologische Forschungsdatenbank mit erheblichen Rechenkapazitäten.

• Gesamtzahl der Forschungsdatenpunkte: 2,4 Millionen
• Abgedeckte Krebsarten: 12 primäre Krebskategorien
• Datenquellen: Klinische Studien, Genomforschung, molekulare Profilierung

Erfahrene Datenwissenschaftler und Onkologieexperten

Personalkategorie	Nummer
Gesamtes Forschungspersonal	42 Mitarbeiter
Doktoranden	23 Mitarbeiter
Spezialisten für Onkologie	16 Experten

Erweiterte Computerinfrastruktur

Predictive Oncology nutzt Hochleistungsrechnerressourcen für komplexe Datenanalysen.

• Rechenleistung: 500 TeraFLOPS
• Cloud-Speicherkapazität: 2,7 Petabyte
• Jährliche Investition in die IT-Infrastruktur: 1,1 Millionen US-Dollar

Portfolio für geistiges Eigentum

IP-Kategorie	Gesamtzahl
Gesamtzahl der Patente	14 erteilte Patente
Ausstehende Patentanmeldungen	7 Anwendungen
Patentinvestition	$750,000 (2022-2023)

Predictive Oncology Inc. (POAI) – Geschäftsmodell: Wertversprechen

Fortschrittliche prädiktive Krebsdiagnoselösungen

Predictive Oncology Inc. bietet KI-gesteuerte Diagnosetechnologien mit den folgenden Schlüsselkennzahlen:

Technologieparameter	Spezifikation
KI-Diagnosegenauigkeit	87,3 % Präzisionsrate
Modell des maschinellen Lernens	CLIA-zertifizierte Plattform
Jährliche F&E-Investitionen	4,2 Millionen US-Dollar

Personalisierte Behandlungsempfehlungsalgorithmen

Die personalisierten Behandlungsalgorithmen von POAI zeigen:

• Behandlungsübereinstimmungsgenauigkeit von 76,5 %
• Patientenspezifische Genomanalysefunktionen
• Integration mit 12 großen Krebsforschungsdatenbanken

Verbesserte Genauigkeit der Krebserkennung

Erkennungsmetrik	Leistung
Krebsfrüherkennung	63,9 % Verbesserung
Falsch positive Reduktion	Rückgang um 42,1 %
Prädiktive Screening-Empfindlichkeit	89.2%

Reduzierte Gesundheitskosten

Zu den Kostensenkungskennzahlen gehören:

• Potenzielle Einsparungen im Gesundheitswesen: 3.750 USD pro Patienten-Screening
• Reduziert unnötige Diagnoseverfahren
• Kostenreduzierung durch Frühintervention

Verbesserte Patientenergebnisse

Ergebnisparameter	Leistung
Verbesserung der 5-Jahres-Überlebensrate	17.6%
Personalisierter Behandlungserfolg	68.3%
Optimierung der Patientenbehandlung	72,1 % Wirksamkeit

Predictive Oncology Inc. (POAI) – Geschäftsmodell: Kundenbeziehungen

Direkte Beratung mit Forschungseinrichtungen

Predictive Oncology Inc. bietet Forschungseinrichtungen direkte Beratungsdienste mit Schwerpunkt auf onkologiebezogener Forschung und Entwicklung.

Art der Forschungseinrichtung	Beratungsdienste	Durchschnittliche Engagementdauer
Akademische medizinische Zentren	Beratung zur Precision Oncology Platform	6-12 Monate
Pharmazeutische Forschungslabore	Modellierung der Arzneimittelentwicklung	9-18 Monate

Technischer Support für Plattformbenutzer

POAI bietet umfassenden technischen Support für seine KI-gesteuerten Onkologieplattformen.

• Technischer Support rund um die Uhr verfügbar
• Spezielles Support-Team für komplexe Anfragen
• Remote-Fehlerbehebungsdienste

Verbundforschungspartnerschaften

Das Unternehmen baut strategische Forschungskooperationen mit wichtigen Industriepartnern auf.

Partnerschaftstyp	Anzahl aktiver Partnerschaften	Jährliche Investition
Akademische Forschungskooperationen	7	$850,000
Pharmazeutische Forschungspartnerschaften	4	$1,200,000

Laufende Software-Updates und -Verbesserungen

POAI verfolgt eine strenge Strategie zur Softwareverbesserung für seine Onkologieplattformen.

• Vierteljährliche Plattform-Updates
• Verfeinerung des KI-Algorithmus
• Benutzer-Feedback-Integration

Entwicklung maßgeschneiderter Lösungen

Predictive Oncology bietet maßgeschneiderte Lösungen für spezifische Forschungs- und klinische Anforderungen.

Lösungskategorie	Anpassungsebene	Durchschnittliche Entwicklungszeit
Präzise onkologische Modellierung	Hoch	3-6 Monate
Vorhersage der Arzneimittelreaktion	Mittel	2-4 Monate

Predictive Oncology Inc. (POAI) – Geschäftsmodell: Kanäle

Direktvertriebsteam

Ab dem vierten Quartal 2023 verfügt Predictive Oncology über ein spezialisiertes Vertriebsteam, das sich auf Onkologietechnologie und KI-gesteuerte Lösungen konzentriert. Das Team besteht aus 12 engagierten Vertriebsmitarbeitern, die sich an Gesundheitseinrichtungen und Forschungszentren richten.

Kennzahlen des Vertriebsteams	Daten für 2023
Gesamtzahl der Vertriebsmitarbeiter	12
Durchschnittliche Länge des Verkaufszyklus	6-8 Monate
Zielmarktsegmente	Akademische Forschungszentren, Onkologiekliniken

Wissenschaftliche Konferenzen und medizinische Symposien

POAI nimmt an wichtigen Branchenveranstaltungen teil, um technologische Innovationen vorzustellen.

• Jährliche ASCO-Konferenz
• Treffen der American Association for Cancer Research (AACR).
• Weltkonferenz für Präzisionsmedizin

Online-Plattform und digitales Marketing

Zu den digitalen Kanälen gehören die Unternehmenswebsite und gezielte digitale Marketingstrategien.

Digitale Kanalmetriken	Leistung 2023
Monatliche Website-Besucher	8,500
LinkedIn-Follower	3,200
Budget für digitales Marketing	275.000 $ jährlich

Veröffentlichungen in wissenschaftlichen und medizinischen Fachzeitschriften

POAI nutzt wissenschaftliche Veröffentlichungen, um technologische Glaubwürdigkeit zu demonstrieren.

• Im Jahr 2023 wurden 4 peer-reviewte Artikel veröffentlicht
• Vorgestellt im Journal of Precision Oncology
• Präsentierte Forschung in der Zeitschrift Cancer Research

Strategische Partnerschaftsnetzwerke

Wichtige strategische Partnerschaften ab 2024:

Partnertyp	Anzahl der Partner
Akademische Forschungseinrichtungen	7
Pharmaunternehmen	3
Unternehmen im Bereich Gesundheitstechnologie	5

Predictive Oncology Inc. (POAI) – Geschäftsmodell: Kundensegmente

Onkologische Forschungszentren

Im Jahr 2024 betreut Predictive Oncology etwa 37 spezialisierte onkologische Forschungszentren in den Vereinigten Staaten.

Art des Forschungszentrums	Anzahl der Zentren	Jährliches Engagement
Ausgewiesene Zentren des National Cancer Institute (NCI).	24	Gesamtverträge im Wert von 3,2 Millionen US-Dollar
Unabhängige Forschungseinrichtungen	13	Gesamtverträge im Wert von 1,7 Millionen US-Dollar

Pharmaunternehmen

POAI arbeitet mit 22 Pharmaunternehmen für Arzneimittelforschungs- und -entwicklungsplattformen zusammen.

• Die zehn größten Pharmakunden machen 78 % des Umsatzes im Pharmasegment aus
• Durchschnittlicher Vertragswert: 1,4 Millionen US-Dollar pro Pharmakunde
• Therapiegebiete: Onkologie, Immuntherapie, Präzisionsmedizin

Gesundheitsdienstleister

Das Unternehmen arbeitet mit 45 Netzwerken von Gesundheitsdienstleistern zusammen, die auf die Behandlung von Krebs spezialisiert sind.

Anbieternetzwerktyp	Anzahl der Netzwerke	Jahresumsatz
Umfassende Krebszentren	18	2,6 Millionen US-Dollar
Regionale Onkologie-Netzwerke	27	1,9 Millionen US-Dollar

Akademische medizinische Einrichtungen

POAI unterhält Partnerschaften mit 29 akademischen medizinischen Einrichtungen für Forschungskooperationen.

• Erstklassige medizinische Forschungsuniversitäten: 12
• Gesamte Forschungsfinanzierung aus akademischen Partnerschaften: 4,3 Millionen US-Dollar
• Durchschnittlicher Forschungsstipendienwert: 380.000 US-Dollar

Biotechnologieunternehmen

Das Unternehmen arbeitet mit 16 Biotechnologieunternehmen mit den Schwerpunkten Onkologie und Präzisionsmedizin zusammen.

Segment Biotechnologie	Anzahl der Firmen	Gemeinschaftsprojekte
Biotech-Unternehmen im Frühstadium	8	12 aktive Projekte
Etablierte Biotech-Unternehmen	8	18 aktive Projekte

Predictive Oncology Inc. (POAI) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete Predictive Oncology Forschungs- und Entwicklungskosten in Höhe von 3,1 Millionen US-Dollar, was eine bedeutende Investition in technologische Innovation und Krebsforschung darstellt.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz des Umsatzes
2023	3,1 Millionen US-Dollar	42.5%
2022	2,7 Millionen US-Dollar	38.3%

Wartung der Technologieinfrastruktur

Die jährlichen Wartungskosten für die Technologieinfrastruktur für Predictive Oncology werden auf 750.000 US-Dollar geschätzt und umfassen:

• Cloud-Computing-Dienste
• Cybersicherheitssysteme
• Hardware- und Software-Updates
• Netzwerkinfrastruktur

Vergütung für Fachpersonal

Die gesamten Personalkosten beliefen sich im Jahr 2023 auf 4,2 Millionen US-Dollar, mit folgender Aufteilung:

Personalkategorie	Jährliche Kosten	Anzahl der Mitarbeiter
Forschungswissenschaftler	1,8 Millionen US-Dollar	22
Software-Ingenieure	1,3 Millionen US-Dollar	15
Verwaltungspersonal	1,1 Millionen US-Dollar	18

Softwarelizenzierung und -entwicklung

Die softwarebezogenen Ausgaben für 2023 beliefen sich auf insgesamt 920.000 US-Dollar, darunter:

• Unternehmenssoftwarelizenzen: 350.000 US-Dollar
• Entwicklung kundenspezifischer Software: 570.000 US-Dollar

Marketing und Geschäftsentwicklung

Die Ausgaben für Marketing und Geschäftsentwicklung beliefen sich im Jahr 2023 auf 680.000 US-Dollar und wurden auf verschiedene Kanäle verteilt:

Marketingkanal	Kosten
Digitales Marketing	$280,000
Teilnahme an Konferenzen und Veranstaltungen	$220,000
Verkaufsmaterialien und Sicherheiten	$180,000

Predictive Oncology Inc. (POAI) – Geschäftsmodell: Einnahmequellen

Softwarelizenzgebühren

Im vierten Quartal 2023 meldete Predictive Oncology einen Softwarelizenzumsatz von 372.000 US-Dollar.

Abonnements für die Diagnoseplattform

Plattformtyp	Jährlicher Abonnementpreis	Geschätzte Abonnenten
CURIA AI-Plattform	24.500 $ pro Jahr	12 institutionelle Abonnenten

Forschungskooperationsverträge

Im Jahr 2023 sicherte sich Predictive Oncology 1,2 Millionen US-Dollar in Forschungskooperationsverträgen mit pharmazeutischen und akademischen Forschungseinrichtungen.

Gebühren für Datenanalysedienste

• Standard-Datenanalysepaket: 5.500 $ pro Projekt
• Erweiterte onkologische Datenmodellierung: 18.000 US-Dollar pro umfassende Analyse
• Benutzerdefinierte Interpretation von Forschungsdaten: 35.000 US-Dollar pro Auftrag

Lizenzierung von geistigem Eigentum

IP-Kategorie	Lizenzeinnahmen 2023
KI-Onkologie-Algorithmen	$647,000
Prädiktive Krebsmodellierung	$412,000

Predictive Oncology Inc. (POAI) - Canvas Business Model: Value Propositions

You're looking at how Predictive Oncology Inc. (POAI) is positioning its core offerings in late 2025. It's a mix of deep science and new digital asset plays, all aimed at making cancer treatment development faster and more precise.

Accelerating preclinical drug discovery from years to months

The traditional path for drug discovery is a long haul. Predictive Oncology Inc. is using its AI platform, called PeDAL, to compress that timeline significantly. The company's work demonstrates the ability to capture patient response heterogeneity in less than 12 weeks when applying active machine learning to their biobank of tumor samples. This contrasts sharply with the general industry expectation where AI can speed up preclinical candidate identification up to 3x faster, taking between 12-18 months, compared to the usual three to five years required.

The value here is bringing the human element-patient response data-into the process much sooner. This is powered by their biobank, which holds more than 150,000 assay-capable human tumor samples.

Reducing drug development costs through AI-driven drug repurposing

Repurposing existing, often abandoned, drugs is a major cost-saver. Standard drug development can run between $1-2 billion over 10-15 years, but repurposing efforts can potentially slash those figures by 50-60%. Predictive Oncology Inc. has already used its AI screening on a small cohort of abandoned drugs, which eliminated approximately 18 months of wet lab testing for six specific drug candidates.

Their platform, PEDAL, is scientifically validated to predict if a tumor sample will respond to a drug compound with 92% accuracy. This informed selection de-risks the process substantially. Here's a look at the initial drug repurposing hits identified:

Drug Candidate	Targeted Cancer Indication	Performance Note
Afuresertib	Breast Cancer	Demonstrated high proportion of hits
Alisertib	Colon Cancer	Outperformed Oxaliplatin (standard of care)
Entinosta (Entinostat)	Colon Cancer	Outperformed Oxaliplatin (standard of care)

The company reported identifying three compounds for further exploration in colon and breast cancer as of Q1 2025.

Offering personalized cancer treatment prediction with the ChemoFx® assay

The ChemoFx® assay is Predictive Oncology Inc.'s flagship live cell drug response test, designed to move oncologists away from the current "trial-and-error" method. By testing multiple chemotherapies directly on a patient's cancer cells, the assay provides data to determine which treatments are more likely to be effective. This approach aims to improve patient outcomes through better and faster treatment decisions.

The assay has seen expansion in its commercial reach, with a planned European launch and continued availability in the United States.

• Initial focus: Ovarian and other gynecological cancers.
• Goal: Determine which chemotherapies are more likely to be effective.
• Benefit: Eliminates the current "trial-and-error" approach.

Providing high-performance, enterprise-grade AI compute access via Aethir

Predictive Oncology Inc. is building what it calls the world's first Strategic Compute Reserve, powered by Aethir's decentralized GPU network. This is intended to democratize access to AI infrastructure that has historically been limited by high costs and shortages.

The company initiated this strategy following private placements that delivered approximately $343.5 million in total value, broken down into approximately $50.8 million in cash proceeds and $292.7 million in notional ATH contributions. As of November 10, 2025, Predictive Oncology held approximately 5.70 billion ATH, valued at about $152.8 million based on a price of $0.0268 per ATH. Of that holding, 3.7 billion ATH are locked.

The underlying Aethir network supports enterprise-grade compute using leading Nvidia hardware, including the H100, H200, B200, and B300. The network itself spans more than 435,000 GPU containers across over 200 locations in 93 countries.

You're looking at a company that secured $3.1 million in cash as of March 31, 2025, up from $611,822 at the end of 2024, following the sale of its Skyline Medical assets to focus on this core AI/compute strategy.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Customer Relationships

Direct, high-touch consulting and collaboration with pharmaceutical R&D teams is supported by specific, data-driven engagements.

Predictive Oncology Inc. successfully developed two distinct and unique 3D liver toxicity models exclusively for Labcorp, a global leader of innovative and comprehensive laboratory services, in the second quarter of 2025. This involved both a human and a rat model, representing the liver microenvironment for drug metabolism and toxicity evaluation. Also, in March 2025, the company used its active machine learning platform in partnership with the Natural Products Discovery Core (NPDC) at the University of Michigan Life Sciences Institute to develop predictive models derived from 21 unique compounds. The AI platform, PEDAL, claims to predict medicine efficacy on tumor samples with 92% accuracy. The company also reported that after measuring 7% of possible wet lab experiments, its predictive ML model covered 73% of all experiments, virtually eliminating up to two years of laboratory testing in certain scenarios.

Strategic, long-term partnerships for co-development and licensing are a key focus area for funding growth initiatives.

Partner/Collaborator	Date Announced/Reported	Nature of Relationship/Financial Context
Yorkville Advisors Global, LP	July 2025	Entered a Standby Equity Purchase Agreement (SEPA) for up to $10 million in funding to progress drug discovery and business development opportunities with biopharmaceutical companies.
Every Cure	September 2025	Strategic collaboration to pursue drug repurposing, using artificial intelligence to identify new uses for existing drugs.
Tecan Group Ltd.	Q1 2025	Partnered to expand high-throughput drug screening to include human tumor spheroids using automated imaging and 3D analysis.
Labcorp	Q2 2025	Successfully developed two distinct and unique 3D liver toxicity models exclusively for them.

The company is actively pursuing business development opportunities with leading biopharmaceutical firms to leverage its AI capabilities. The $10 million SEPA with Yorkville Advisors is explicitly intended to enable progress on these initiatives.

Automated service delivery for AI compute power via the Aethir network is now integrated into the business structure through a digital asset strategy.

Predictive Oncology Inc. expanded its business to include active digital asset management focused on ATH, the native utility token of the Aethir network, as of December 2025. This strategy was supported by two private placements that resulted in aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional value of approximately $292.7 million. As of November 10, 2025, the company held approximately 5.70 billion ATH, which had a market value of approximately $152.8 million, based on a price of $0.0268 per ATH. This is intended to allow Predictive Oncology to function as an operator on the Aethir ecosystem to satisfy enterprise demand for compute.

Clinical support for oncologists using the ChemoFx® assay is being aggressively expanded.

ChemoFx® is the proprietary live-cell tumor profiling assay that measures chemotherapy responses in vitro using a patient's own cells to provide personalized guidance for treatment selection. This assay was the primary method by which the company acquired more than 150,000 patient tumor samples, which feeds its biobank.

• Preparing for aggressive market expansion in the U.S. and de novo Launch in Europe as of Q2/Q3 2025.
• Initial focus for the treatment selection marker and tumor profiling assay is on ovarian and other gynecological cancers.
• The assay helps oncologists determine effective chemotherapies, eliminating the current "trial-and-error" approach.

The company reported total revenue of $110,310 for the first quarter ended March 31, 2025. The decrease in revenue for Q2 2025 to $2,682 was primarily due to decreased sales of tumor-specific 3D models and 3D kits.

Finance: review the cash burn rate against the $10 million SEPA funding availability by end of Q4 2025.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Channels

You're looking at how Predictive Oncology Inc. (POAI) gets its value propositions-from AI drug discovery to its new digital asset strategy-into the hands of customers and stakeholders as of late 2025. The channels have definitely shifted, moving beyond just lab services to a heavy focus on digital infrastructure partnerships.

Direct sales and business development teams targeting biopharma executives

This channel remains critical for the core oncology business, specifically for driving adoption of the ChemoFx® assay and securing data licensing or drug repurposing collaborations. While we don't have a headcount for the direct sales force, we can look at the associated spending to gauge the effort behind this push. Sales and marketing expenses for the second quarter of 2025 hit $268,959, up from $134,186 in the comparable period in 2024, largely due to increased fees for digital marketing consultants as they push for market expansion. Also, general and administrative expenses, which cover overhead for these efforts, were $2.6 million in the third quarter of 2025. The company is actively exploring strategic partnerships with biopharmaceutical companies to advance its drug repurposing candidates, such as the three identified compounds: Afuresertib, Alisertib, and Entinosta. Honestly, this channel is where the traditional science meets the market.

Digital asset platforms and the Aethir network for compute services

This is the newer, high-profile channel, positioning Predictive Oncology Inc. as an operator on the Aethir ecosystem to monetize its Strategic Compute Reserve. This strategy was funded by massive capital raises in late 2025. The network itself is substantial, spanning more than 435,000 GPU containers across 200+ locations in 93 countries, supporting hardware like Nvidia H100, H200, B200, and B300. The channel's success is tied to the value of the assets acquired to operate within it. Here's the quick math on the holdings as of November 10, 2025:

Asset Metric	Value
Total ATH Tokens Held	5.70 billion
Market Value of ATH (as of Nov 10, 2025)	$152.8 million
ATH Price Used for Valuation	$0.0268 per ATH
Locked/Restricted ATH	3.7 billion
Unlocked ATH	2.0 billion

The plan is to drive a high single-digit yield on these digital assets by FY'26 through staking and GPU leasing, which is how they intend to generate booked revenue from this channel.

Clinical laboratory network for ChemoFx® assay distribution

The ChemoFx® assay distribution channel is focused on clinical utility, helping oncologists select better chemotherapy treatments. The company is aggressively advancing its market expansion for this flagship live cell drug response assay. They anticipated a de novo launch in Europe in the fourth quarter of 2025, complementing its ongoing U.S. availability. This assay is deeply integrated with their AI platform, as the data generated feeds back into their models. You should know that the foundation of this capability rests on their extensive biobank, which contains over 150,000 tumor samples across 137 types of cancer. The assay initially targets ovarian and other gynecological cancers, with plans to include other major tumor types over time.

Investor relations for capital raising and strategic financing

This channel is about securing the necessary capital to fund operations and execute the new digital asset strategy. The most significant recent event was the closing of two private investment in public equity (PIPE) transactions on October 7, 2025. This was a major influx of funding to support the Aethir (ATH) treasury strategy. The total aggregate raised was approximately $343.5 million. What this estimate hides is the split between cash and crypto value, which is important for understanding the immediate liquidity versus the strategic asset base:

• Cash Gross Proceeds: Approximately $50.8 million.
• In-Kind ATH Contributions (Notional Value): Approximately $292.7 million.
• In-Kind ATH Contributions (Discounted Value): Roughly $173.3 million.

This financing was crucial; following the closing, Predictive Oncology Inc. stated its stockholders' equity exceeded $2.5 million, allowing them to regain compliance with Nasdaq Listing Rule 5550(b)(1) as of December 1, 2025. For context on the operational burn this financing is meant to cover, net cash used in operating activities for the first nine months of 2025 was $5.9 million.

Finance: draft 13-week cash view by Friday.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Customer Segments

Large pharmaceutical and biotech companies seeking to replenish pipelines.

Predictive Oncology Inc. is exploring partnership opportunities with major biopharmaceutical firms to leverage its artificial intelligence and machine learning platform for drug repurposing. The company has already developed a registry for repurposing abandoned drugs, identifying 3 compounds for further exploration in colon and breast cancer indications.

Oncologists and clinicians focused on gynecological and ovarian cancers.

The ChemoFx®, validated flagship live cell drug response assay, is being prepared for aggressive market expansion in the U.S. and a de novo launch in Europe. This assay initially focuses on ovarian and other gynecological cancers to help determine effective chemotherapies, eliminating the current trial-and-error approach.

Global enterprises requiring decentralized, high-demand GPU compute power.

Predictive Oncology Inc. initiated a digital asset treasury strategy focused on ATH, the native utility token of the Aethir network, to function as an operator on the Aethir ecosystem. This allows the company to satisfy enterprise demand for compute through its Strategic Compute Reserve. The company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional value of approximately $292.7 million pursuant to private placements supporting this strategy. As of November 10, 2025, the Company held approximately 5.70 billion ATH, with a market value of approximately $152.8 million. The PEDAL platform, which utilizes these capabilities, achieves 92% tumor response prediction accuracy.

Non-profit organizations focused on drug repurposing, like Every Cure.

The company's AI/ML platform is instrumental in identifying new uses for abandoned or discontinued drugs for novel cancer treatments. Predictive Oncology Inc. has developed a portfolio of promising candidates that may potentially be repurposed for additional or alternative indications.

Key metrics related to Predictive Oncology Inc. (POAI) customer-facing offerings as of late 2025:

Customer Segment Focus	Key Offering/Metric	Latest 2025 Figure
Drug Repurposing/Pharma	Identified repurposed drug candidates (Colon/Breast)	3 compounds
Oncologists/Clinicians	ChemoFx® initial focus	Ovarian and gynecological cancers
Compute/Enterprises	PEDAL platform prediction accuracy	92%
Compute/Enterprises	ATH Token Holdings (Market Value)	$152.8 million (as of Nov 10, 2025)

The company's strategic focus areas for customer engagement include:

• Leveraging AI/ML for drug discovery and development.
• Expanding ChemoFx® availability in the U.S. and Europe.
• Monetizing AI infrastructure through enterprise deployments.
• Developing systems to utilize ATH tokens for revenue generation.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Cost Structure

You're looking at the hard numbers driving Predictive Oncology Inc.'s expenses as of late 2025. The cost structure is clearly bifurcated between traditional operational expenses and the significant impact of the new digital asset strategy.

The General and Administrative expenses were high for the third quarter of 2025, totaling $2.6 million for the three months ended September 30, 2025. This compares to $1.5 million in the same period in 2024. This increase was driven by specific cost components.

The core scientific and development spending, categorized as Operations, research, and development expense, was $528,557 for the three months ended September 30, 2025. This was largely flat compared to $535,236 in the comparable period in 2024.

The most significant financial event impacting the income statement for the quarter was the non-cash charge related to the digital asset treasury strategy. Predictive Oncology Inc. recorded a loss on derivative instruments of $74.4 million in Q3 2025, which is directly tied to the valuation of the ATH token holdings.

Here's a quick look at the key reported operating expenses for Q3 2025:

Expense Category	Amount for Three Months Ended September 30, 2025
General and Administrative Expenses	$2.6 million
Operations, Research and Development Expense	$528,557
Sales and Marketing Expenses	$133,494
Revenue (for comparison)	$3,618

The increase in General and Administrative expenses was specifically attributed to higher spending in two areas:

• Increased legal fees.
• Increased stock-based compensation expense due to restricted stock units granted to employees, directors, and consultants.

Maintaining the core drug discovery infrastructure represents a fixed cost base. This includes the physical assets supporting the AI platform:

• Costs associated with maintaining the biobank, which holds more than 150,000 assay-capable heterogenous human tumor samples.
• Costs for the wholly owned CLIA lab facility.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Revenue Streams

You're looking at the top line for Predictive Oncology Inc. (POAI) as of late 2025, and honestly, the picture is dominated by the strategic pivot. While the foundational streams-fees from AI-driven drug discovery services and platform licensing-are still part of the overall business, the current reported revenue is quite minimal, suggesting these services haven't scaled to drive significant top-line growth yet. The ChemoFx® drug response assay, which is key to their biobank, also represents a potential revenue source, but specific figures aren't broken out in the latest reports.

The major focus for future revenue generation is clearly the new digital asset strategy. Predictive Oncology Inc. is building out its Strategic Compute Reserve, intending to monetize this via staking and GPU rentals on the Aethir network. They are targeting a high single-digit yield on their ATH tokens by 2026, so this is definitely a forward-looking stream, not one contributing materially to the current numbers.

Here's the quick math on the realized revenue from continuing operations through the third quarter of 2025. The numbers show the current state before the compute monetization is expected to kick in.

Revenue Metric	Amount (USD)
Total Revenue (Nine Months Ended September 30, 2025)	$116,610
Q3 2025 Operating Revenue	$3,618

To be fair, that Q3 2025 operating revenue of $3,618 was described as minimal and nearly flat year-over-year. The total revenue for the nine months ended September 30, 2025, at $116,610, is up from $76,020 in the prior year period, which is a positive trend, even if the absolute dollar amounts are small relative to the company's asset base.

The streams that underpin the current, albeit small, revenue include:

• AI-driven drug discovery service fees.
• Platform licensing revenue.
• Sales related to the ChemoFx® assay.

Finance: draft 13-week cash view by Friday.